2023
DOI: 10.1093/ofid/ofad604
|Get access via publisher |Cite
|
Sign up to set email alerts

Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

Abstract: As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug–drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 7 publications
0
1
0
Order By: Relevance
“…The equations can be implemented in PBPK models during drug development to address unstudied clinical scenarios related, for instance, to the management of DDIs 36 , 53 and evaluation of the pharmacokinetics in special populations in order to guide clinical decisions. 54 , 55 …”
Section: Discussionmentioning
confidence: 99%
“…The equations can be implemented in PBPK models during drug development to address unstudied clinical scenarios related, for instance, to the management of DDIs 36 , 53 and evaluation of the pharmacokinetics in special populations in order to guide clinical decisions. 54 , 55 …”
Section: Discussionmentioning
confidence: 99%